Sage Vida Weight Management
Personalized, evidence-based, and built for long-term health
Sage Vida’s approach to weight management is grounded in obesity medicine, longevity science, and individualized care. Rather than applying a single protocol, each plan is tailored to the patient’s metabolic profile, body composition, medical history, lifestyle constraints, and long-term health goals. Please don’t be sucked in by the quick strip mall-type clinic that sees you only to provide the shot and move you on your way. Your long-term health is at stake.
​
Weight-loss medications, when used, are integrated into a broader strategy that prioritizes muscle preservation, adequate protein intake, resistance training, and metabolic health monitoring. Nutrition guidance emphasizes sustainability and physiologic support rather than restriction, while physical activity recommendations are realistic, progressive, and aligned with functional capacity.
​
Equally important, Sage Vida recognizes obesity as a chronic condition that requires ongoing support, informed decision-making, and adaptability over time. Treatment plans are designed to evolve, with clear expectations, anticipatory guidance around medication use or discontinuation, and a focus on preserving strength, independence, and quality of life as patients age.
A thoughtful, informed approach starts with a conversation
​
If you are considering weight-loss medication, struggling with weight regain, or seeking a sustainable path that protects your health beyond the scale, Sage Vida offers individualized weight management consultations grounded in evidence and long-term outcomes.
Schedule a comprehensive weight management visit to discuss your goals, review options, and determine whether a personalized, longevity-focused approach is right for you.
A chronic-disease, longevity-focused approach to sustainable health
Weight management is not a matter of willpower or short-term dieting. Obesity is a chronic, relapsing, neurobehavioral disease influenced by genetics, hormonal signaling, metabolic adaptation, environment, and lived experience (Obesity Medicine Association [OMA], 2024). Effective treatment requires a long-term, individualized strategy that addresses physiology, nutrition, physical activity, and behavior together rather than in isolation.
At Sage Vida, weight management is approached as a health optimization strategy, prioritizing metabolic resilience, preservation of lean mass, functional capacity, and long-term disease risk reduction rather than scale weight alone.
The Basics: What you should know before you begin
Weight loss triggers predictable biological responses. As body fat is reduced, appetite-regulating hormones shift to increase hunger while resting energy expenditure declines, creating a physiologic drive toward weight regain (Sumithran & Proietto, 2013; MacLean et al., 2011). These responses are not personal failures; they are well-documented survival mechanisms.
Clinically meaningful weight loss does not require dramatic reductions. A sustained loss of 5–10% of body weight is associated with improvements in insulin sensitivity, blood pressure, lipid profiles, mobility, and quality of life (OMA, 2024). The goal is not rapid weight loss, but durable improvement in metabolic and functional health.
The Skinny on Weight-Loss Medications: Benefits, limitations, and trade-offs
Anti-obesity medications, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual incretin therapies, act centrally and peripherally to reduce appetite, increase satiety, and counteract biologic resistance to weight loss (Davies et al., 2021; Wadden et al., 2020). When combined with structured lifestyle intervention, these agents can produce substantial and clinically meaningful weight loss.
However, medication-induced weight loss is not risk-free. Clinical trials and real-world data demonstrate that a portion of total weight loss includes lean body mass, particularly when protein intake and resistance training are inadequate (Neeland et al., 2024; Karakasis, 2024). Additional reported adverse effects include gastrointestinal symptoms, fatigue, micronutrient deficiencies, and hair shedding, particularly in the setting of rapid weight reduction.
At Sage Vida, medications are used strategically, with explicit attention to nutrition quality, protein adequacy, physical activity, and monitoring of body composition rather than reliance on medication alone.
Hair Loss and GLP-1 Therapy: What the evidence shows
Hair shedding has been reported more often in people using GLP-1 medications. A 2025 scoping review found that this is usually non-scarring hair loss, most often a temporary condition called telogen effluvium, which can occur during periods of rapid weight loss (Rojas Lopez et al., 2025).
Current evidence suggests this hair loss is not caused directly by the medication itself. Instead, it is more likely related to factors such as rapid weight loss, metabolic stress, and inadequate intake of protein or key nutrients. Real-world data presented in 2024 also showed a higher rate of non-scarring hair loss in people taking GLP-1 medications compared with similar individuals not using these drugs, highlighting the importance of nutrition and early counseling during treatment (Medicom Conference Reports, 2024).
What Happens When Medications Are Stopped: Why weight regain is common and expected
When GLP-1 medications are stopped, weight regain is common—not because of failure, but because the body’s hunger signals reactivate. In the STEP 4 clinical trial, people who stopped semaglutide regained much of the weight they had lost, while those who continued treatment maintained their results (Rubino et al., 2021).
After weight loss, the hormone ghrelin increases, making you feel hungrier, while leptin, which helps signal fullness, becomes less effective. Together, these changes increase appetite and reduce satiety, driving the body to regain weight. Longer-term studies show this pattern continues without ongoing medication or structured lifestyle support (Ryan et al., 2024).
Commitment and Lifestyle Requirements: What actually supports long-term success
Sustainable weight management requires parallel investment in nutrition, physical activity, and behavioral strategies. Adequate protein intake is essential for preserving lean mass during weight loss and maintaining resting energy expenditure (OMA, 2024; Phillips et al., 2016). Resistance training and regular physical activity improve insulin sensitivity, cardiovascular health, and long-term weight maintenance (OMA, 2024).
Behavioral interventions such as goal setting, motivational interviewing, relapse planning, and addressing environmental triggers are not optional adjuncts; they are foundational components of effective obesity care (Wing & Phelan, 2005).
A Longevity-Focused Perspective
Why muscle and metabolism matter
From a longevity standpoint, preservation of muscle mass and metabolic function is central to healthy aging. As emphasized by Peter Attia, MD, loss of lean mass compromises strength, independence, insulin sensitivity, and long-term health outcomes, even when body weight decreases (Attia, 2023).
At Sage Vida, weight management strategies are evaluated through a broader lens: Does this approach preserve strength, function, and metabolic health over time? If not, the plan is reassessed.
References
Attia, P. (2023). Outlive: The science and art of longevity. Harmony.
​
Karakasis, P., Patoulias, D., Fragakis, N., & Mantzoros, C. S. (2025). Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: A systematic review and network meta-analysis. Metabolism, 164, 156113.
https://doi.org/10.1016/j.metabol.2024.156113
​
MacLean, P. S., Blundell, J. E., Mennella, J. A., & Batterham, R. L. (2017). Biological control of appetite: A daunting complexity. Obesity (Silver Spring, Md.), 25 Suppl 1(Suppl 1), S8–S16. https://doi.org/10.1002/oby.21771
​
Medicom Conference Reports. (2024). GLP-1 receptor agonists linked to higher risk of non-scarring hair loss in real-world cohort. https://conferences.medicom-publishers.com/content/conference-reports/glp-1ras-linked-to-higher-risk-of-non-scarring-hair-loss-in-real-world-cohort/
​
Neeland, I. J., et al. (2024). Changes in lean body mass with glucagon-like peptide-1 receptor agonists. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15436
​
Obesity Medicine Association. (2024). Fundamentals of obesity treatment.
​
Rojas Lopez, R. F., Lynett Barrera, D., Amaya Muñoz, M. C., & Saavedra Diaz, M. P. (2025). Alopecia as an emerging adverse effect associated with glucagon-like peptide-1 (GLP-1) receptor agonists for weight loss: A scoping review. Cureus, 17(8), e90021. https://doi.org/10.7759/cureus.90021
​
Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224
​
Ryan, D. H., et al. (2024). Long-term weight loss effects of semaglutide in obesity: Four-year results from SELECT. Nature Medicine. https://doi.org/10.1038/s41591-024-02996-7
​
Sumithran, P., & Proietto, J. (2013). The defence of body weight: A physiological basis for weight regain after weight loss. Clinical Science, 124(4), 231–241. https://doi.org/10.1042/CS20120223
​
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., & STEP 1 Study Group. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
​
Wing, R. R., & Phelan, S. (2005). Long-term weight loss maintenance. American Journal of Clinical Nutrition, 82(1), 222S–225S. https://doi.org/10.1093/ajcn/82.1.222S